Literature DB >> 29112016

B Lymphoblastic Leukemia/Lymphoma With Burkitt-like Morphology and IGH/MYC Rearrangement: Report of 3 Cases in Adult Patients.

Yiting Li1, Gunjan Gupta2, Ari Molofsky1, Yi Xie1, Nader Shihabi3, Jane McCormick4, Elaine S Jaffe5.   

Abstract

Isolated MYC rearrangement without other recurrent genetic abnormalities is rare in B lymphoblastic leukemia/lymphoma (B-ALL/LBL), with most cases reported in pediatric patients. We report 3 adult cases with lymphoblasts showing a precursor B cell immunophenotype, and isolated MYC/IGH translocation. All 3 cases occurred in male patients with initial presentation of diffuse lymphadenopathy. Cases 1 and 2 had B-ALL with significantly increased lymphoblasts in peripheral blood and bone marrow. Case 3, a patient with human immunodeficiency virus infection, had the diagnosis of B-LBL made on a retroperitoneal lymph node biopsy and had no peripheral blood or bone marrow involvement. The leukemic and lymphoma cells in all 3 cases demonstrated Burkitt lymphoma-like morphology with deeply basophilic cytoplasm and numerous cytoplasmic vacuoles. However, all 3 had immature immunophenotypes including expression of terminal deoxynucleotidyl transferase (TdT), absence of BCL6, and dim-to-negative CD45. CD20 was largely negative in 2 of 3 cases. All 3 had confirmed MYC/IGH translocation, but lacked rearrangements of BCL2 or BCL6. EBV was negative by Epstein-Barr virus encoded small RNA in situ hybridization. Treatment protocols varied, including both high-risk ALL-type (protocol 8707) and high-grade lymphoma regimens (hyper-CVAD [cyclophosphamide, vincristine, adriamycin, and dexamethasone]), but no patient achieved continuous complete remission. These cases seem to represent a distinct biological phenomenon, in which a MYC translocation may be acquired at an immature stage of differentiation, thus manifesting features of both B-ALL/LBL and Burkitt lymphoma.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29112016      PMCID: PMC5762415          DOI: 10.1097/PAS.0000000000000982

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  27 in total

Review 1.  Precursor B-cell acute lymphoblastic leukaemia with FAB L3 (i.e., Burkitt's leukaemia/lymphoma) morphology and co-expression of monoclonal surface light chains and Tdt: report of a unique case and review of the literature.

Authors:  Bryce Higa; Serhan Alkan; Kevin Barton; Milind Velankar
Journal:  Pathology       Date:  2009       Impact factor: 5.306

Review 2.  New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia.

Authors:  Elias Jabbour; Susan O'Brien; Marina Konopleva; Hagop Kantarjian
Journal:  Cancer       Date:  2015-04-17       Impact factor: 6.860

3.  Activation of the c-myc oncogene in a precursor-B-cell blast crisis of follicular lymphoma, presenting as composite lymphoma.

Authors:  D De Jong; B M Voetdijk; G C Beverstock; G J van Ommen; R Willemze; P M Kluin
Journal:  N Engl J Med       Date:  1988-05-26       Impact factor: 91.245

4.  FAB L3 type of B-cell acute lymphoblastic leukemia (B-ALL) without chromosome abnormalities.

Authors:  N Imamura; D M Mtasiwa; H Ota; T Inada; A Kuramoto
Journal:  Am J Hematol       Date:  1990-11       Impact factor: 10.047

Review 5.  The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

Authors:  Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

6.  Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas.

Authors:  P Bertrand; C Bastard; C Maingonnat; F Jardin; C Maisonneuve; M-N Courel; P Ruminy; J-M Picquenot; H Tilly
Journal:  Leukemia       Date:  2007-01-18       Impact factor: 11.528

7.  Burkitt lymphoma/leukaemia transformed from a precursor B cell: clinical and molecular aspects.

Authors:  Rocio Hassan; Fabricio Felisbino; Claudio Gustavo Stefanoff; Virginia Pires; Claudete E Klumb; Jane Dobbin; Héctor N Seuánez; Ilana Zalcberg Renault
Journal:  Eur J Haematol       Date:  2007-11-15       Impact factor: 2.997

8.  The 14q+ chromosome in pre-B-ALL.

Authors:  Y Kaneko; J D Rowley; I Check; D Variakojis; J W Moohr
Journal:  Blood       Date:  1980-11       Impact factor: 22.113

9.  Chromosomal breakpoints and structural alterations of the c-myc locus differ in endemic and sporadic forms of Burkitt lymphoma.

Authors:  P G Pelicci; D M Knowles; I Magrath; R Dalla-Favera
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

Review 10.  MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management.

Authors:  Qingqing Cai; L Jeffrey Medeiros; Xiaolu Xu; Ken H Young
Journal:  Oncotarget       Date:  2015-11-17
View more
  6 in total

Review 1.  Updates in the Pathology of Precursor Lymphoid Neoplasms in the Revised Fourth Edition of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues.

Authors:  Christopher Wenzinger; Eli Williams; Alejandro A Gru
Journal:  Curr Hematol Malig Rep       Date:  2018-08       Impact factor: 3.952

2.  IG-MYC + neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomas.

Authors:  Rabea Wagener; Cristina López; Kortine Kleinheinz; Julia Bausinger; Sietse M Aukema; Inga Nagel; Umut H Toprak; Julian Seufert; Janine Altmüller; Holger Thiele; Christof Schneider; Julia Kolarova; Jeongbin Park; Daniel Hübschmann; Eva M Murga Penas; Hans G Drexler; Andishe Attarbaschi; Randi Hovland; Eigil Kjeldsen; Michael Kneba; Udo Kontny; Laurence de Leval; Peter Nürnberg; Ilske Oschlies; David Oscier; Brigitte Schlegelberger; Stephan Stilgenbauer; Wilhelm Wössmann; Matthias Schlesner; Birgit Burkhardt; Wolfram Klapper; Elaine S Jaffe; Ralf Küppers; Reiner Siebert
Journal:  Blood       Date:  2018-10-03       Impact factor: 22.113

3.  Burkitt leukemia with precursor B-cell features that developed after ruxolitinib treatment in a patient with hydroxyurea-refractory JAK2V617F-myeloproliferative neoplasm.

Authors:  Katsuhiro Fukutsuka; Futoshi Iioka; Fumiyo Maekawa; Miho Nakagawa; Chiyuki Kishimori; Masahiko Hayashida; Shunsuke Tagawa; Takashi Akasaka; Gen Honjo; Hitoshi Ohno
Journal:  J Clin Exp Hematop       Date:  2021-05-14

4.  Risk Factors for Relapse of Childhood B Cell Acute Lymphoblastic Leukemia.

Authors:  Rongrong Zhang; Haiyan Zhu; Yufang Yuan; Jiou Zhao; Xiaochun Yang; Zhaofang Tian
Journal:  Med Sci Monit       Date:  2020-07-03

5.  Transformation of a low-grade follicular lymphoma into a composite lymphoma combining a high-grade B-cell lymphoma and a lymphoblastic neoplasm expressing Terminal deoxynucleotidyl Transferase: a case report.

Authors:  Antonin Bouroumeau; Eleonore Kaphan; Clémentine Legrand; Tatiana Raskovalova; Gautier Szymanski; Claire Vettier; Christine Lefebvre; Marie-Christine Jacob; Anne McLeer; Michel Peuchmaur; Rémy Gressin; Hervé Sartelet
Journal:  J Med Case Rep       Date:  2020-07-27

6.  Dramatic increase in gene mutational burden after transformation of follicular lymphoma into TdT+ B-lymphoblastic leukemia/lymphoma.

Authors:  Jonathan P Belman; Wenzhao Meng; Hong Yi Wang; Jie Li; Honore T Strauser; Aaron M Rosenfeld; Qian Zhang; Eline T Luning Prak; Mariusz Wasik
Journal:  Cold Spring Harb Mol Case Stud       Date:  2020-02-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.